Parathyroid hormone oral - Unigene

Drug Profile

Parathyroid hormone oral - Unigene

Alternative Names: 768974; GSK 768974; PTH 1-31; PTH 131A; PTH oral - Unigene

Latest Information Update: 12 Jun 2015

Price : $50

At a glance

  • Originator Unigene Laboratories
  • Class Calcium regulators; Osteoporosis therapies; Peptide hormones
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Postmenopausal osteoporosis

Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 02 Jul 2013 Discontinued - Phase-II for Postmenopausal osteoporosis in USA (PO)
  • 08 Mar 2012 Parathyroid hormone oral - Unigene is available for licensing (\www.unigene.com\)
  • 06 Dec 2011 Unigene terminates exclusive worldwide license agreement with GlaxoSmithKline and regains all rights to its oral parathyroid hormone product
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top